ChiCTR-TRC-14005009
正在进行
/
/
/
2014-07-25
/
/
stroke
體外反搏與經顱磁刺激聯合療法對中風病人手部運動功能康復的研究
體外反搏與經顱磁刺激聯合療法對中風病人手部運動功能康復的研究
體外反搏與經顱磁刺激聯合療法對中風病人手部運動功能康復
随机平行对照
Ⅳ期
RCT
/
Division of Neurology, Dept of Medicine and Therapeutics, PWH, The Chinese University of Hong Kong
/
80
/
2014-09-20
1990-01-01
/
1) patients aged 18 or above; 2) first-ever ischemic subcortical stroke with onset time less than 21 days; 3) hand weakness (distal MRC 1- 5-) as a result of stroke; 4) recordable MEPs over ipsilesional hemisphere; 5) intracranial hemorrhage excluded by brain computed tomography (CT) / magnetic resonance imaging (MRI); 6) the patient or his/her legally acceptable representative is willing to provide written informed consent.；
请登录查看For TMS : 1) personal history of epilepsy; 2) metallic implants in any part of body; 3) implanted cardiac pacemaker, defibrillator, medication pump or any other implanted electronics; 4) severe skull fracture, serious head injury, history of brain or spinal cord surgery; 5) brain tumour or other significant non-ischemic brain lesion on CT/MRI; 6) administration of drugs that potentially lower seizure threshold; 7) active malignancy; 8) severe co-existing systemic diseases: eg. renal failure (creatinine more than 300 umol/L, if known), cirrhosis, severe dementia or psychosis; 9) inability to be followed up at regular interval; 10) pegnancy or breast-feeding. For ECP: 11) evidence for cardioembolic stroke such as atrial fibrillation and rheumatic heart disease; 12) sustained hypertension (systolic higher than 180mmHg or diastolic higher than 100mmHg); 13) subject has thrombocytopenia (platelet count less than 100,000/mm3); 14) evidence of arteriovenous malformation, arteriovenous fistula or aneurysm; 15) evidence of diabetic retinopathy.；
请登录查看Medicine & Therapeutics, The Chinese University of Hong Kong
/
Medicine & Therapeutics, The Chinese University of Hong Kong的其他临床试验
Division of Neurology, Dept of Medicine and Therapeutics, PWH的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04